SAN FRANCISCO The FDA town hall meeting at this year's edition of Transcatheter Cardiovascular Therapeutics lacked some of the depth of discussions seen in previous years' meetings, but made up for that lack with some rather controversial comments about the 510(k) process by a member of the Institute of Medicine (IOM) team that reviewed the process.